Demographic, pulmonary function and BAL cell differential
| Placebo | Azithromycin | p Value | |
|---|---|---|---|
| n=10 | n=10 | ||
| Age (years) | 60.7 (53.1–66.1) | 65.7 (62.1–68.2) | 0.09 |
| Male (%) | 6 (60) | 7 (70) | 0.64 |
| Caucasian (%) | 9 (90) | 10 (100) | 0.31 |
| BMI | 27.7 (26.3–29.9) | 26.7 (25.0–32.2) | 0.63 |
| Current smoker (%) | 4 (40) | 2 (20) | 0.33 |
| Pack-years | 46.5 (32.2–53.2) | 35.5 (22.5–48.5) | 0.31 |
| PFT | |||
| FVC* | 98.2 (89.0–110.3) | 99.7 (85.8–105.4) | 0.68 |
| FEV1* | 90.4 (81.2–96.0) | 90.5 (81.5–100.9) | 0.14 |
| FEV1/FVC | 66.9 (61.8–79.0) | 72.7 (67.4–74.3) | 0.31 |
| FVC post-BD* | 96.8 (90.1–105.0) | 98.0 (84.2–104.6) | 0.71 |
| FEV1 post-BD* | 93.9 (85.5–104.1) | 96.0 (84.9–109.0) | 0.55 |
| FEV1/FVC post-BD | 70.8 (65.5–84.2) | 73.0 (70.6–78.4) | 0.55 |
| COPD GOLD criteria | |||
| GOLD 1 | 3 | 2 | 0.61 |
| GOLD 2 | 1 | 0 | 0.31 |
| GOLD criteria not met | 6 | 8 | 0.33 |
| Imaging | |||
| Emphysema score9 11 | 0.83 (0.66–1.25) | 1.08 (0.41–1.66) | 0.91 |
| % lung voxels <−950 HU | 21 (16–23) | 17 (12–25) | 0.65 |
| Centrilobular predominant (%) | 9 (90) | 7 (70) | 0.26 |
| BAL cells (%) | |||
| Macrophages | 90.8 (88.2–92.4) | 89.8 (85.0–95.3) | 0.91 |
| Lymphocytes | 6.5 (4.1–9.4) | 4.3 (3.3–10.7) | 0.52 |
| Neutrophils | 1.8 (1.1–2.9) | 1.6 (1.2–4.6) | 0.68 |
| Eosinophils | 0.0 (0.0–0.3) | 0.1 (0.0–1.0) | 0.73 |
| PneumotypeSPT (%) | 4 (40) | 4 (40) | 1.00 |
Data are presented as percentage or median (IQR).
p Values based on Mann-Whitney U test or χ2 test (continuous or categorical variables, respectively).
*Percentage predicted.
ATS, American Thoracic Society; BAL, bronchoalveolar lavage; BD, bronchodilator (albuterol); BMI, body mass index; ERS, European Respiratory Society; GOLD, Global Initiative for Chronic Obstructive Lung Disease; PFT, pulmonary function testing according to standard ATS/ERS guidelines; PneumotypeSPT, pneumotype for supraglottic predominant taxa.